BioNTech Rallies on Positive mRNA Cancer Trial Results from Competitor
Shares of BioNTech (NASDAQ:BNTX) rose following positive interim Phase 3 trial data for Moderna and Merck’s personalized mRNA cancer therapy, intismeran. The treatment showed significant improvements in recurrence-free survival among high-risk melanoma patients who had undergone surgery. This result has bolstered confidence across the broader mRNA oncology sector. While BioNTech is not directly involved with this trial, investors are considering whether Moderna’s success validates its own pipeline of mRNA-based cancer therapies. The company is awaiting results from a Phase 3 interim analysis for BNT113 in head-and-neck squamous cell carcinoma and has multiple other late-stage trials underway across various oncology programs. BioNTech remains well-capitalized, with €16.6 billion in cash as of June 2026, allowing it to continue funding its extensive R&D portfolio despite rising costs from ongoing clinical development.
Topics: BioNTech pipeline validation mRNA therapy Phase 3 trial results